Molecular targets and novel therapeutic avenues in soft-tissue sarcoma

被引：8

作者：

Elkrief, A. ^{[1
,2
]}

Alcindor, T. ^{[1
]}

机构：

[1] McGill Univ, Cedars Canc Ctr, Dept Oncol, Hlth Ctr, Montreal, PQ, Canada

[2] Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Dept Oncol, Montreal, PQ, Canada

来源：

CURRENT ONCOLOGY | 2020年 / 27卷

关键词：

Sarcoma; chemotherapy; targeted therapy; immunotherapy; GIANT-CELL TUMOR; EUROPEAN ORGANIZATION; OPEN-LABEL; PHASE-II; ANGIOSARCOMA; PACLITAXEL; EXPRESSION; SORAFENIB; EFFICACY; KINASE;

D O I：

10.3747/co.27.5631

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Soft-tissue sarcoma (STS) represents a heterogeneous group of rare tumours, and a significant number of affected patients will develop metastatic disease. Outcomes in the population with metastatic disease are generally poor, especially after progression on standard chemotherapy. The advent of personalized medicine has permitted oncologists to offer targeted treatment, thus addressing the limited treatment options and poor prognosis after progression on first-line chemotherapy. In this review, we delineate the existing data and therapeutic successes with respect to existing and emerging molecular targets in STS and options for immunotherapy in STS. Our review also summarizes emerging clinical trials that are currently recruiting patients.

引用

页码：34 / 40

页数：7

共 52 条

[1] Multiple metastases from histologically benign intraarticular diffuse-type tenosynovial giant cell tumor: a case report [J].

Asano, Naofumi ;

Yoshida, Akihiko ;

Kobayashi, Eisuke ;

Yamaguchi, Takehiko ;

Kawai, Akira .

HUMAN PATHOLOGY, 2014, 45 (11) :2355-2358

[2] Landscape of Microsatellite Instability Across 39 Cancer Types [J].

Bonneville, Russell ;

Krook, Melanie A. ;

Kautto, Esko A. ;

Miya, Jharna ;

Wing, Michele R. ;

Chen, Hui-Zi ;

Reeser, Julie W. ;

Yu, Lianbo ;

Roychowdhury, Sameek .

JCO PRECISION ONCOLOGY, 2017, 1 :1-15

[3] Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis [J].

Brahmi, Mehdi ;

Vinceneux, Armelle ;

Cassier, Philippe A. .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (02) :1-9

[4] CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study [J].

Cassier, Philippe A. ;

Italiano, Antoine ;

Gomez-Roca, Carlos A. ;

Le Tourneau, Christophe ;

Toulmonde, Maud ;

Cannarile, Michael A. ;

Ries, Carola ;

Brillouet, Anne ;

Mueller, Claudia ;

Jegg, Anna-Maria ;

Broeske, Ann-Marie ;

Dembowski, Markus ;

Bray-French, Katharine ;

Freilinger, Christine ;

Meneses-Lorente, Georgina ;

Baehner, Monika ;

Harding, Ross ;

Ratnayake, Jayantha ;

Abiraj, Keelara ;

Gass, Nathalie ;

Noh, Karen ;

Christen, Randolph D. ;

Ukarma, Lidia ;

Bompas, Emmanuelle ;

Delord, Jean-Pierre ;

Blay, Jean-Yves ;

Ruettinger, Dominik .

LANCET ONCOLOGY, 2015, 16 (08) :949-956

[5]

Chawla SP, 2018, ANN ONCOL S8, V29

[6] Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259 T Cells in Synovial Sarcoma [J].

D'Angelo, Sandra P. ;

Melchiori, Luca ;

Merchant, Melinda S. ;

Bernstein, Donna ;

Glod, John ;

Kaplan, Rosandra ;

Grupp, Stephan ;

Tap, William D. ;

Chagin, Karen ;

Binder, Gwendolyn K. ;

Basu, Samik ;

Lowther, Daniel E. ;

Wang, Ruoxi ;

Bath, Natalie ;

Tipping, Alex ;

Betts, Gareth ;

Ramachandran, Indu ;

Navenot, Jean-Marc ;

Zhang, Hua ;

Wells, Daniel K. ;

Van Winkle, Erin ;

Kari, Gabor ;

Trivedi, Trupti ;

Holdich, Tom ;

Pandite, Lini ;

Amado, Rafael ;

Mackall, Crystal L. .

CANCER DISCOVERY, 2018, 8 (08) :944-957

[7] Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials [J].

D'Angelo, Sandra P. ;

Mahoney, Michelle R. ;

Van Tine, Brian A. ;

Atkins, James ;

Milhem, Mohammed M. ;

Jahagirdar, Balkrishna N. ;

Antonescu, Cristina R. ;

Horvath, Elise ;

Tap, William D. ;

Schwartz, Gary K. ;

Streicher, Howard .

LANCET ONCOLOGY, 2018, 19 (03) :416-426

[8] Estrogen receptor-β expression in extraabdominal fibromatoses -: An analysis of 40 cases [J].

Deyrup, AT ;

Tretiakova, M ;

Montag, AG .

CANCER, 2006, 106 (01) :208-213

[9] Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children [J].

Drilon, A. ;

Laetsch, T. W. ;

Kummar, S. ;

DuBois, S. G. ;

Lassen, U. N. ;

Demetri, G. D. ;

Nathenson, M. ;

Doebele, R. C. ;

Farago, A. F. ;

Pappo, A. S. ;

Turpin, B. ;

Dowlati, A. ;

Brose, M. S. ;

Mascarenhas, L. ;

Federman, N. ;

Berlin, J. ;

El-Deiry, W. S. ;

Baik, C. ;

Deeken, J. ;

Boni, V. ;

Nagasubramanian, R. ;

Taylor, M. ;

Rudzinski, E. R. ;

Meric-Bernstam, F. ;

Sohal, D. P. S. ;

Ma, P. C. ;

Raez, L. E. ;

Hechtman, J. F. ;

Benayed, R. ;

Ladanyi, M. ;

Tuch, B. B. ;

Ebata, K. ;

Cruickshank, S. ;

Ku, N. C. ;

Cox, M. C. ;

Hawkins, D. S. ;

Hong, D. S. ;

Hyman, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08) :731-739

[10]

Fata F, 1999, CANCER-AM CANCER SOC, V86, P2034, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO

← 1 2 3 4 5 6 →